NeuroKaire is a technology company.
NeuroKaire has raised $20.0M across 2 funding rounds.
NeuroKaire has raised $20.0M in total across 2 funding rounds.
NeuroKaire is a precision medicine biotech company developing "brain-in-a-dish" technology that converts patient blood samples into induced pluripotent stem cells (iPSCs) and then into patient-specific neurons to predict drug responses for CNS disorders like major depression, anxiety, schizophrenia, bipolar, PTSD, ADHD, Alzheimer’s, and Parkinson’s.[1][2][3] It serves patients, physicians, and biopharma partners by solving the problem of trial-and-error prescribing in psychiatry and neurology, where it often takes 12-18 months to find effective treatments, through its launched product BrightKaire—a blood-based test achieving 79.3% accuracy in matching antidepressants by integrating neuronal plasticity markers, genetics, medical history, AI-driven computer vision, and a comprehensive biobank.[1][3][4] The company operates a dual business model of clinical lab tests for providers and patients alongside pharma partnerships for drug development and patient stratification, with growth momentum from BrightKaire's 2024 launch, expanding healthcare networks, and 2025 pharma deals targeting Alzheimer’s.[3][6]
NeuroKaire, formerly Genetika+, was founded in 2018 in Israel as a women-led company by CEO Dr. Talia Cohen Solal—an Oxford, UCL, and Columbia alumna transitioning from bench research—and co-founder Dr. Daphna Laifenfeld, former head of personalized medicine at Teva Pharmaceuticals with a Technion doctorate focused on depression.[4][5] The idea emerged from recognizing pharmacogenetics' limitations in providing pharmacodynamic insights for mental health, leading to a platform that tests drugs on patient-derived neurons to shorten the path to effective treatment amid widespread depression challenges.[4][5] Early traction built through a team of 17 scientists developing the iPSC technology, culminating in BrightKaire's launch and a robust biobank of hundreds of thousands of data points from diverse profiles.[1][3]
NeuroKaire rides the precision medicine wave in neuroscience, addressing CNS drug development's high failure rates (often >90%) by providing mechanistic brain insights that bridge lab-to-clinic gaps in psychiatry and neurology.[3][6] Timing aligns with surging demand for personalized treatments amid mental health crises, AI advancements in biology, and biopharma's push for patient stratification to cut costs and boost trial success—exemplified by its pharma partnerships and Alzheimer’s expansion.[3] Market forces like rising healthcare burdens from depression (affecting millions) and iPSC tech maturation favor it, while its platform influences the ecosystem by accelerating therapies, informing digital health via data insights, and enabling companion diagnostics for commercialization.[2][5][6]
NeuroKaire is poised to scale BrightKaire adoption through healthcare integrations while deepening pharma ties for Alzheimer’s and beyond, leveraging its data asset for novel targets and stratified trials.[3] Trends like AI-biology convergence, expanding iPSC applications, and payer demands for evidence-based psych treatments will propel growth, potentially evolving its influence from niche predictor to CNS standard via biobank-powered platforms. This positions NeuroKaire to transform suffering in brain health, fulfilling its mission of precision psychiatry realized.
NeuroKaire has raised $20.0M in total across 2 funding rounds.
NeuroKaire's investors include B Capital Group, Craft Ventures, Grace Beauty Capital, Springdale Ventures, Vayner RSE.
NeuroKaire has raised $20.0M across 2 funding rounds. Most recently, it raised $10.0M Venture Round in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $10.0M Venture Round | B Capital Group | |
| Sep 1, 2021 | $10.0M Series A | B Capital Group, Craft Ventures, Grace Beauty Capital, Springdale Ventures, Vayner RSE |